FibroGen, Inc. (LON:0IL8)
London
· Delayed Price · Currency is GBP · Price in USD 0.2812
-0.0064 (-2.23%)
At close: Apr 17, 2025
FibroGen Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 29.62 | 46.8 | 140.73 | 235.31 | 176.32 | Upgrade
|
| Revenue Growth (YoY) | -36.71% | -66.74% | -40.19% | 33.46% | -31.28% | Upgrade
|
| Cost of Revenue | 111.25 | 295.07 | 299.95 | 449.19 | 260.64 | Upgrade
|
| Gross Profit | -81.63 | -248.27 | -159.21 | -213.88 | -84.32 | Upgrade
|
| Selling, General & Admin | 49.33 | 86.48 | 141.81 | 134.65 | 107.56 | Upgrade
|
| Operating Expenses | 49.33 | 86.48 | 141.81 | 134.65 | 107.56 | Upgrade
|
| Operating Income | -130.96 | -334.75 | -301.03 | -348.53 | -191.88 | Upgrade
|
| Interest Expense | -8.25 | -8.1 | -1.44 | -1.08 | -2.4 | Upgrade
|
| Interest & Investment Income | 5.3 | 7.87 | 7.6 | - | 5.81 | Upgrade
|
| Earnings From Equity Investments | - | - | 1.57 | 1.01 | -0.2 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | - | -1.08 | - | Upgrade
|
| EBT Excluding Unusual Items | -133.91 | -334.98 | -293.29 | -349.68 | -188.67 | Upgrade
|
| Merger & Restructuring Charges | -19.45 | -12.61 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | -0.27 | -0.01 | - | -0.26 | Upgrade
|
| Pretax Income | -153.37 | -323.22 | -293.3 | -289.68 | -188.93 | Upgrade
|
| Income Tax Expense | -0.27 | -0.25 | 0.36 | 0.35 | 0.36 | Upgrade
|
| Earnings From Continuing Operations | -153.1 | -322.97 | -293.65 | -290.02 | -189.29 | Upgrade
|
| Earnings From Discontinued Operations | 105.52 | 38.74 | - | - | - | Upgrade
|
| Net Income | -47.58 | -284.23 | -293.65 | -290.02 | -189.29 | Upgrade
|
| Net Income to Common | -47.58 | -284.23 | -293.65 | -290.02 | -189.29 | Upgrade
|
| Shares Outstanding (Basic) | 100 | 97 | 94 | 92 | 90 | Upgrade
|
| Shares Outstanding (Diluted) | 100 | 97 | 94 | 92 | 90 | Upgrade
|
| Shares Change (YoY) | 2.82% | 3.98% | 1.33% | 2.78% | 3.72% | Upgrade
|
| EPS (Basic) | -0.48 | -2.92 | -3.14 | -3.14 | -2.11 | Upgrade
|
| EPS (Diluted) | -0.48 | -2.92 | -3.14 | -3.14 | -2.11 | Upgrade
|
| Free Cash Flow | -138.27 | -317.54 | -149.67 | -87.42 | 77.61 | Upgrade
|
| Free Cash Flow Per Share | -1.38 | -3.26 | -1.60 | -0.95 | 0.86 | Upgrade
|
| Gross Margin | -275.59% | - | -113.13% | -90.89% | -47.82% | Upgrade
|
| Operating Margin | -442.13% | -715.23% | -213.90% | -148.12% | -108.82% | Upgrade
|
| Profit Margin | -160.63% | -607.29% | -208.66% | -123.25% | -107.36% | Upgrade
|
| Free Cash Flow Margin | -466.78% | -678.46% | -106.35% | -37.15% | 44.02% | Upgrade
|
| EBITDA | -128.27 | -324.82 | -290.42 | -333.72 | -169.83 | Upgrade
|
| EBITDA Margin | - | - | -206.36% | -141.82% | -96.32% | Upgrade
|
| D&A For EBITDA | 2.69 | 9.93 | 10.6 | 14.81 | 22.05 | Upgrade
|
| EBIT | -130.96 | -334.75 | -301.03 | -348.53 | -191.88 | Upgrade
|
| EBIT Margin | - | - | -213.90% | -148.12% | -108.82% | Upgrade
|
| Revenue as Reported | 29.62 | 46.8 | 140.73 | 235.31 | 176.32 | Upgrade
|
Updated Mar 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.